Citation Impact
Citing Papers
Cell culture-grown hepatitis C virus is infectious in vivo and can be recultured in vitro
2006 StandoutNobel
Neutralizing antibody response during acute and chronic hepatitis C virus infection
2004 StandoutNobel
Plasmacytoid dendritic cells initiate a complex chemokine and cytokine network and are a viable drug target in chronic HCV patients
2007 StandoutNobel
Crippling life support for SARS-CoV-2 and other viruses through synthetic lethality
2020 StandoutNobel
Evidence for a functional RNA element in the hepatitis C virus core gene
2007 StandoutNobel
Mouse models of acute and chronic hepacivirus infection
2017 StandoutScienceNobel
Proteomics of HCV virions reveals an essential role for the nucleoporin Nup98 in virus morphogenesis
2016 StandoutNobel
Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance
2018 Standout
The natural course of HCV infection and the need for treatment
2008
Treatment failure in hepatitis C: Mechanisms of non-response
2008
Pan-Genotype Hepatitis E Virus Replication in Stem Cell–Derived Hepatocellular Systems
2017 StandoutNobel
Treatment predictors of a sustained virologic response in hepatitis B and C
2008
Intracellular Proton Conductance of the Hepatitis C Virus p7 Protein and Its Contribution to Infectious Virus Production
2010
Hepatitis C Virus Blocks Interferon Effector Function by Inducing Protein Kinase R Phosphorylation
2009
Association Between Sustained Virological Response and All-Cause Mortality Among Patients With Chronic Hepatitis C and Advanced Hepatic Fibrosis
2012
Hepatitis B virus-related decompensated liver cirrhosis: Benefits of antiviral therapy
2012
SEC14L2 enables pan-genotype HCV replication in cell culture
2015 StandoutNatureNobel
Accuracy of Risk Scores for Patients With Chronic Hepatitis B Receiving Entecavir Treatment
2013
A Sustained Viral Response Is Associated With Reduced Liver-Related Morbidity and Mortality in Patients With Hepatitis C Virus
2009
Genetic variation in IL28B and spontaneous clearance of hepatitis C virus
2009 StandoutNature
Hepatocellular carcinoma
2018 Standout
Multi-input chemical control of protein dimerization for programming graded cellular responses
2019 StandoutNobel
Hepatitis C virus genotype 3: a genotype that is not ‘easy-to-treat’
2014
DNA recognition by an RNA-guided bacterial Argonaute
2017 StandoutNobel
Naturally occurring NS3-protease-inhibitor resistant mutant A156T in the liver of an untreated chronic hepatitis C patient
2007
Regulation of hepatic innate immunity by hepatitis C virus
2013
A Multi-Step Process of Viral Adaptation to a Mutagenic Nucleoside Analogue by Modulation of Transition Types Leads to Extinction-Escape
2010
Telbivudine versus lamivudine and entecavir for treatment-naïve decompensated hepatitis B virus-related cirrhosis
2016
A Sustained Virologic Response Reduces Risk of All-Cause Mortality in Patients With Hepatitis C
2011
Lethal Mutagenesis of Hepatitis C Virus Induced by Favipiravir
2016 StandoutNobel
Hepatocellular carcinoma
2012 Standout
Nucleotide Polymerase Inhibitor Sofosbuvir plus Ribavirin for Hepatitis C
2013
A Humanized Mouse Model to Study Hepatitis C Virus Infection, Immune Response, and Liver Disease
2011 StandoutNobel
Use of Liver Imaging and Biopsy in Clinical Practice
2017
Can we use HCC risk scores to individualize surveillance in chronic hepatitis B infection?
2015
Diagnosis, management, and treatment of hepatitis C: An update # † ‡
2008 Standout
Efficacy of Entecavir With or Without Tenofovir Disoproxil Fumarate for Nucleos(t)ide-Naïve Patients With Chronic Hepatitis B
2012
Metazoan MicroRNAs
2018 Standout
Interferon-based therapy of hepatitis C
2007
Efficacy of Tenofovir-based Rescue Therapy in Lamivudine-resistant Chronic Hepatitis B Patients With Failure of Lamivudine and Adefovir Combination
2015
Aging of Hepatitis C Virus (HCV)-Infected Persons in the United States: A Multiple Cohort Model of HCV Prevalence and Disease Progression
2009
Importance of IL28B gene polymorphisms in hepatitis C virus genotype 2 and 3 infected patients
2010
Extinction of Hepatitis C Virus by Ribavirin in Hepatoma Cells Involves Lethal Mutagenesis
2013
Mechanisms of Hepatic Fibrogenesis
2008 Standout
Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: Updated criteria and genotype assignment web resource
2013 StandoutNobel
Role of antiviral treatment for HCC prevention
2014
Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals
2016
Incidence of Hepatocellular Carcinoma and Associated Risk Factors in Hepatitis C-Related Advanced Liver Disease
2008
Expert opinion on the treatment of patients with chronic hepatitis C
2008
Impact of donor and recipient IL28B rs12979860 genotypes on hepatitis C virus liver graft reinfection
2010
An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases
2011
Argonaute CLIP Defines a Deregulated miR-122-Bound Transcriptome that Correlates with Patient Survival in Human Liver Cancer
2017 StandoutNobel
Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance
2009 StandoutNature
Sustained virological response to interferon plus ribavirin reduces liver‐related complications and mortality in patients coinfected with human immunodeficiency virus and hepatitis C virus†
2009
A diverse range of gene products are effectors of the type I interferon antiviral response
2011 StandoutNatureNobel
Hepatitis C Virus-Specific Directly Acting Antiviral Drugs
2013
Mixing the right hepatitis C inhibitor cocktail
2010
Global control of hepatitis C: where challenge meets opportunity
2013
Analysis of Functional Differences between Hepatitis C Virus NS5A of Genotypes 1–7 in Infectious Cell Culture Systems
2012
The HCV Life Cycle: In vitro Tissue Culture Systems and Therapeutic Targets
2014 Standout
Late HDV RNA Relapse After Peginterferon Alpha-Based Therapy of Chronic Hepatitis Delta
2014
Understanding the hepatitis C virus life cycle paves the way for highly effective therapies
2013 StandoutNobel
Risk of hepatocellular carcinoma in chronic hepatitis B: Assessment and modification with current antiviral therapy
2015
Hepatocellular Carcinoma
2011 Standout
Hepatitis E virus mutations associated with ribavirin treatment failure result in altered viral fitness and ribavirin sensitivity
2016
Telaprevir and Peginterferon with or without Ribavirin for Chronic HCV Infection
2009
Effect of Virological Response to Entecavir on the Development of Hepatocellular Carcinoma in Hepatitis B Viral Cirrhotic Patients: Comparison Between Compensated and Decompensated Cirrhosis
2014
Antiviral Therapy Reduces Risk of Hepatocellular Carcinoma in Patients With Hepatitis C Virus–Related Cirrhosis
2009
Changes in sequences of core region, interferon sensitivity‐determining region and interferon and ribavirin resistance‐determining region of hepatitis C virus genotype 1 during interferon‐alpha and ribavirin therapy, and efficacy of retreatment
2012
What Are the Promising New Therapies in the Field of Chronic Hepatitis C After the First-Generation Direct-Acting Antivirals?
2012
Epidemiology of hepatocellular carcinoma in the United States: Where are we? Where do we go?
2014
Boceprevir for Untreated Chronic HCV Genotype 1 Infection
2011 Standout
Computational Docking Study of p7 Ion Channel from HCV Genotype 3 and Genotype 4 and Its Interaction with Natural Compounds
2015
Sequence variation in hepatitis C virus nonstructural protein 5A predicts clinical outcome of pegylated interferon/ribavirin combination therapy†
2008
Prevention of hepatocellular carcinoma in chronic viral hepatitis B and C infection
2013
Outcome of Sustained Virological Responders With Histologically Advanced Chronic Hepatitis C†,‡,§,¶
2010
Hepatic gene expression during treatment with peginterferon and ribavirin: Identifying molecular pathways for treatment response
2007
Tumor Necrosis Factor Inhibits Spread of Hepatitis C Virus Among Liver Cells, Independent From Interferons
2017 StandoutNobel
Treatment of HCV Infection by Targeting MicroRNA
2013 Standout
Replication of hepatitis C virus
2007 StandoutNobel
Hepatitis C Virus RNA Functionally Sequesters miR-122
2015 StandoutNobel
Prediction of risk for hepatocellular carcinoma by response of serum α‐fetoprotein to entecavir therapy
2015
Hepatitis C virus glycoproteins mediate pH-dependent cell entry of pseudotyped retroviral particles
2003 StandoutNobel
Hepatocellular Carcinoma
2019 Standout
Hepatocellular Carcinoma in Patients with a Sustained Response to Anti-Hepatitis C Therapy
2015
AASLD guidelines for treatment of chronic hepatitis B
2015
In vivo evidence for ribavirin-induced mutagenesis of the hepatitis E virus genome
2016
Telaprevir for Previously Treated Chronic HCV Infection
2010
PCR Technologies for Point of Care Testing: Progress and Perspectives
2017
Hepatitis C guidance: AASLD‐IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus
2015
Ultrastructural analysis of hepatitis C virus particles
2013 StandoutNobel
Protease inhibitor therapy for hepatitis C virus-infection
2018
The efficacy and safety of entecavir in patients with chronic hepatitis B- associated liver failure: a meta-analysis
2015
Deep Sequencing Reveals Mutagenic Effects of Ribavirin during Monotherapy of Hepatitis C Virus Genotype 1-Infected Patients
2013
Characterization of nonprimate hepacivirus and construction of a functional molecular clone
2015 StandoutNobel
Human broadly neutralizing antibodies to the envelope glycoprotein complex of hepatitis C virus
2012 StandoutNobel
Bright Side of Lignin Depolymerization: Toward New Platform Chemicals
2018 Standout
Next Generation of Fluorine-Containing Pharmaceuticals, Compounds Currently in Phase II–III Clinical Trials of Major Pharmaceutical Companies: New Structural Trends and Therapeutic Areas
2016 Standout
Full-length genome sequences of hepatitis C virus subtype 4f
2007
A bacterial Argonaute with noncanonical guide RNA specificity
2016 StandoutNobel
Eradication of Hepatitis C Virus in Patients Successfully Treated for Chronic Hepatitis C
2008
Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease
2010
Meta‐analysis: oral anti‐viral agents in adults with decompensated hepatitis B virus cirrhosis
2012
Response of Hepatitis C Virus to Long-Term Passage in the Presence of Alpha Interferon: Multiple Mutations and a Common Phenotype
2013 StandoutNobel
Fibrosis — A Common Pathway to Organ Injury and Failure
2015 Standout
Cellular cofactors affecting hepatitis C virus infection and replication
2007 StandoutNobel
Efficacy and safety of entecavir and/or tenofovir in hepatitis B compensated and decompensated cirrhotic patients in clinical practice
2013
Clearance of replicating hepatitis C virus replicon RNAs in cell culture by small interfering RNAs
2002 StandoutNobel
Global control of hepatitis C virus
2015 Science
Effect of Ribavirin on the Mutation Rate and Spectrum of Hepatitis C Virus In Vivo
2009
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
2018 Standout
Successful anti-scavenger receptor class B type I (SR-BI) monoclonal antibody therapy in humanized mice after challenge with HCV variants with in vitro resistance to SR-BI-targeting agents
2014 StandoutNobel
Activation of naïve B lymphocytes via CD81, a pathogenetic mechanism for hepatitis C virus-associated B lymphocyte disorders
2005 StandoutNobel
Global cancer statistics, 2012
2015 Standout
The Hepatitis C Virus NS4B Protein Can trans -Complement Viral RNA Replication and Modulates Production of Infectious Virus
2008
Therapeutically Targeting Rna Viruses Via Lethal Mutagenesis
2008
Photothermal Nanomaterials: A Powerful Light-to-Heat Converter
2023 Standout
Fast detection of liver fibrosis with collagen-binding single-nanometer iron oxide nanoparticles via T 1 -weighted MRI
2023 StandoutNobel
Works of Wolf Peter Hofmann being referenced
Hepatitis D virus‐specific cytokine responses in patients with chronic hepatitis delta before and during interferon alfa‐treatment
2011
A new standard of care for the treatment of chronic HCV infection
2011
Placebo-controlled trial of 400 mg amantadine combined with peginterferon alfa-2a and ribavirin for 48 weeks in chronic hepatitis C virus-1 infection
2008
Severe lactic acidosis during treatment of chronic hepatitis B with entecavir in patients with impaired liver function†
2009
Antiviral therapy of chronic hepatitis C in patients with advanced liver disease and after liver transplantation
2009
Correlation of amino acid variations within nonstructural 4B protein with initial viral kinetics during interferon‐alpha‐based therapy in HCV‐1b‐infected patients
2006
Hepatitis C virus-related resistance mechanisms to interferon α-based antiviral therapy
2004
Entecavir treatment for chronic hepatitis B: Adaptation is not needed for the majority of naïve patients with a partial virological response
2011
Mutagenic Effect of Ribavirin on Hepatitis C Nonstructural 5B Quasispecies In Vitro and During Antiviral Therapy
2006
Comparison of transcription mediated amplification (TMA) and reverse transcription polymerase chain reaction (RT-PCR) for detection of hepatitis C virus RNA in liver tissue
2005
Therapeutic vaccine IC41 as late add-on to standard treatment in patients with chronic hepatitis C
2009
Ribavirin mode of action in chronic hepatitis C: from clinical use back to molecular mechanisms
2008
Antiviral Combination Therapy for Treatment of Chronic Hepatitis B, Hepatitis C, and Human Immunodeficiency Virus Infection
2008
Screening forIL28Bgene variants identifies predictors of hepatitis C therapy success
2010
Comparison of Conventional PCR with Real-Time PCR and Branched DNA-Based Assays for Hepatitis C Virus RNA Quantification and Clinical Significance for Genotypes 1 to 5
2006
New therapeutic strategies needed for advanced disease
2009
Virological response to entecavir is associated with a better clinical outcome in chronic hepatitis B patients with cirrhosis
2012
Viral Determinants of Resistance to Treatment in Patients with Hepatitis C
2007
Sustained Virologic Response and Clinical Outcomes in Patients with Chronic Hepatitis C and Advanced Fibrosis
2007